Literature DB >> 16223962

Psychiatric complications in Parkinson disease.

Daniel Weintraub1, Matthew B Stern.   

Abstract

Although Parkinson disease (PD) is primarily considered a movement disorder, the high prevalence of psychiatric complications suggests that it is more accurately conceptualized as a neuropsychiatric disease. Affective disorders, cognitive impairment, and psychosis are particularly common in PD and are associated with excess disability, worse quality of life, poorer outcomes, and caregiver distress. Yet, in spite of this and their frequent occurrence, there is incomplete understanding of the epidemiology, phenomenology, risk factors, neuropathophysiology, and optimal treatment strategies for these disorders. Psychiatric complications are typically comorbid, and there is great intra- and inter-individual variability in presentation. The hallmark neuropathophysiological changes that occur in PD plus the association between exposure to dopaminergic medications and certain psychiatric disorders suggest a neurobiological basis for most psychiatric symptoms, although psychological factors are probably involved in the development of affective disorders. Although antidepressants, antipsychotics, and cognition-enhancing agents are commonly prescribed in PD, controlled studies demonstrating efficacy and tolerability of these drugs are virtually nonexistent. Because of the high prevalence and complexity of psychiatric complications in PD, geriatric psychiatrists are in a position to offer valuable consultation and clinical care to this population. This article provides an overview of the epidemiology, pathophysiology, clinical presentation, and management of the most common psychiatric complications in PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223962     DOI: 10.1176/appi.ajgp.13.10.844

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  30 in total

1.  Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study.

Authors:  C Arbus; V Gardette; C E Cantet; S Andrieu; F Nourhashémi; L Schmitt; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

2.  Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning.

Authors:  Jim Grigsby; Angela G Brega; Rachael E Bennett; James A Bourgeois; Andreea L Seritan; Glenn K Goodrich; Randi J Hagerman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

3.  Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study.

Authors:  Katherine Oehlberg; Frances K Barg; Gregory K Brown; Donna Taraborelli; Matthew B Stern; Daniel Weintraub
Journal:  J Geriatr Psychiatry Neurol       Date:  2008-06       Impact factor: 2.680

4.  Prevalence of depression among older Americans: the Aging, Demographics and Memory Study.

Authors:  David C Steffens; Gwenith G Fisher; Kenneth M Langa; Guy G Potter; Brenda L Plassman
Journal:  Int Psychogeriatr       Date:  2009-06-12       Impact factor: 3.878

5.  Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial.

Authors:  Roseanne D Dobkin; Matthew Menza; Lesley A Allen; Michael A Gara; Margery H Mark; Jade Tiu; Karina L Bienfait; Jill Friedman
Journal:  Am J Psychiatry       Date:  2011-06-15       Impact factor: 18.112

6.  Assessing depression and factors possibly associated with depression during the course of Parkinson's disease.

Authors:  Amy H Farabaugh; Joseph J Locascio; Liang Yap; Maurizio Fava; Stella Bitran; Jessica L Sousa; John H Growdon
Journal:  Ann Clin Psychiatry       Date:  2011-08       Impact factor: 1.567

7.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

8.  Course of psychiatric symptoms and global cognition in early Parkinson disease.

Authors:  Patricia de la Riva; Kara Smith; Sharon X Xie; Daniel Weintraub
Journal:  Neurology       Date:  2014-08-15       Impact factor: 9.910

9.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

10.  Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.

Authors:  Daniel Ecker; Alexander Unrath; Jan Kassubek; Michael Sabolek
Journal:  BMC Neurol       Date:  2009-06-10       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.